{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:24:48Z","timestamp":1783790688853,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Morphine is the most used opioid for dyspnea, but other opioids such as oxycodone and fentanyl are increasingly used, and opioid switching to these is sometimes undertaken. No studies have verified the effectiveness of opioid switching for relief of dyspnea. We retrospectively investigated the effectiveness of opioid switching for dyspnea and its predictors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients with opioid switching for dyspnea during hospitalization at Komaki City Hospital from January 2019 to August 2022 were included. Opioid switching was defined as a change to another opioid, and the assessment period for evaluating the effectiveness and adverse events of opioid switching was set as 1\u00a0week. Patients with Numeric Rating Scale or Japanese version of the Support Team Assessment Schedule reduction for dyspnea of at least 1, or with clear improvement based on medical records, were considered valid. Mitigating factors for dyspnea were identified using logistic regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 976 patients with opioid switching, 57 patients had opioid switching for relief of dyspnea. Of these, opioid switching was effective in 21 patients (36.8%). In a multivariate analysis, older patients (odds ratio: 5.52, 95% CI: 1.50\u201320.20, P\u00a0&amp;lt;\u00a00.01), short prognosis for post-opioid switching (odds ratio: 0.20, 95% CI: 0.04\u20130.87, P\u00a0=\u00a00.03) and cachexia (odds ratio: 0.12, 95% CI: 0.02\u20130.64, P\u00a0&amp;lt;\u00a00.01) were significantly associated with opioid switching effects for dyspnea. There were no serious adverse events after opioid switching.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study indicates that opioid switching for dyspnea may have some effect. Furthermore, opioid switching for dyspnea may be more effective in older patients and less effective in terminally ill patients or in those with cachexia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae008","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:16:57Z","timestamp":1707304617000},"page":"549-555","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of opioid switching for dyspnea and its predictors in cancer patients: a single-center retrospective observational study"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-5830","authenticated-orcid":false,"given":"Yoshihiro","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Departments of Pharmacy, Komaki City Hospital , Komaki, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shion","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]},{"name":"Aichi Gakuin University , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]},{"name":"Aichi Gakuin University , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]},{"name":"Aichi Gakuin University , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Urano","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]},{"name":"Aichi Gakuin University , School of Pharmacy, , Nagoya, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Okita","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Komaki City Hospital , Komaki, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Komaki City Hospital , Komaki, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Odagiri","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Komaki City Hospital , Komaki, Aichi ,","place":["Japan"]},{"name":"Department of Palliative Care, Seino Kosei Hospital, Gifu Seino Medical Center , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy, Komaki City Hospital , Komaki, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2025030818255084900_ref1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S1478951503030499","article-title":"Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers","volume":"1","author":"Booth","year":"2003","journal-title":"Palliat Support Care"},{"key":"2025030818255084900_ref2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/med\/9780199656097.003.0082","volume-title":"Oxford Textbook of Palliative Medicine","author":"Chan","year":"2015","edition":"5th"},{"key":"2025030818255084900_ref3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1049909108327588","article-title":"Dyspnea: a bad prognosis symptom at the end of life","volume":"26","author":"Cuervo Pinna","year":"2009","journal-title":"Am J Hosp Palliat Care"},{"key":"2025030818255084900_ref4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0885-3924(00)00160-3","article-title":"The course of symptom frequency and intensity in advanced cancer patients followed at home","volume":"20","author":"Mercadante","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jpainsymman.2009.09.017","article-title":"Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study","volume":"39","author":"Currow","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pon.1304","article-title":"Dyspnea experience and management strategies in patients with lung cancer","volume":"17","author":"Henoch","year":"2008","journal-title":"Psychooncology"},{"key":"2025030818255084900_ref7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/jpm.2016.0145","article-title":"Treatment recommendations for respiratory symptoms in cancer patients: clinical guidelines from the Japanese Society for Palliative Medicine","volume":"19","author":"Yamaguchi","year":"2016","journal-title":"J Palliat Med"},{"key":"2025030818255084900_ref8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.20.03465","article-title":"Management of dyspnea in advanced cancer: ASCO guideline","volume":"39","author":"Hui","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025030818255084900_ref9","first-page":"CD011008","article-title":"Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness","volume":"2019","author":"Barnes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025030818255084900_ref10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10147-023-02362-6","article-title":"Opioids for the management of dyspnea in cancer patients: a systematic review and meta-analysis","volume":"28","author":"Takagi","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2025030818255084900_ref11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40265-022-01780-6","article-title":"Cancer pain treatment strategies in patients with cancer","volume":"82","author":"Mercadante","year":"2022","journal-title":"Drugs"},{"key":"2025030818255084900_ref12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jpainsymman.2019.06.006","article-title":"The current practice of opioid for cancer dyspnea: the result from the nationwide survey of Japanese palliative care physicians","volume":"58","author":"Yamaguchi","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0029665108007131","article-title":"An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer","volume":"67","author":"McMillan","year":"2008","journal-title":"Proc Nutr Soc"},{"key":"2025030818255084900_ref14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1017\/S1478951504040507","article-title":"Reliability and validity of the Japanese version of the support team assessment schedule (STAS-J)","volume":"2","author":"Miyashita","year":"2004","journal-title":"Palliat Support Care"},{"key":"2025030818255084900_ref15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpainsymman.2015.10.004","article-title":"Minimal clinically important difference in the physical, emotional, and total symptom distress scores of the Edmonton symptom assessment system","volume":"51","author":"Hui","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely-available easy-to-use software \u201cEZR\u201d (easy R) for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025030818255084900_ref17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jpainsymman.2020.11.037","article-title":"How successful is parenteral oxycodone for relieving terminal cancer dyspnea compared with morphine? A multicenter prospective observational study","volume":"62","author":"Mori","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jpainsymman.2016.05.023","article-title":"EffenDys-fentanyl buccal tablet for the relief of episodic breathlessness in patients with advanced cancer: a multicenter, open-label, randomized, morphine-controlled, crossover, phase II trial","volume":"52","author":"Simon","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpainsymman.2007.08.016","article-title":"Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline","volume":"36","author":"Charles","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"2025030818255084900_ref20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00520-008-0479-0","article-title":"Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study","volume":"17","author":"Clemens","year":"2009","journal-title":"Support Care Cancer"},{"key":"2025030818255084900_ref21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.21037\/tlcr-22-512","article-title":"Effectiveness and safety of opioids for dyspnea in patients with lung cancer: secondary analysis of multicenter prospective observational study","volume":"11","author":"Taniguchi","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"2025030818255084900_ref22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/pmr.2020.0050","article-title":"Physician-perceived predictive factors for the effectiveness of drugs for treating cancer dyspnea: results of a nationwide survey of Japanese palliative care physicians","volume":"1","author":"Matsuda","year":"2020","journal-title":"Palliat Med Rep"},{"key":"2025030818255084900_ref23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcsm.12499","article-title":"The relationship between the BMI-adjusted weight loss grading system and quality of life in patients with incurable cancer","volume":"11","author":"Daly","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025030818255084900_ref24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1089\/jpm.2021.0562","article-title":"Prevalence, clinical characteristics, and management of episodic dyspnea in advanced lung cancer outpatients: a multicenter nationwide study-the INSPIRA-DOS study","volume":"25","author":"Juli\u00e0-Torras","year":"2022","journal-title":"J Palliat Med"},{"key":"2025030818255084900_ref25","first-page":"38","article-title":"CONUT: a tool for controlling nutritional status. First validation in a hospital population","volume":"20","author":"Ignacio De Ul\u00edbarri","year":"2005","journal-title":"Nutr Hosp"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/5\/549\/57434825\/hyae008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/5\/549\/57434825\/hyae008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T18:26:05Z","timestamp":1741458365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/5\/549\/7601771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae008","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,2,6]]}}}